As Novo Nordisk transitions from the leadership of longtime CEO Lars Fruergaard Jørgensen to newly appointed chief Maziar ...

Danish drugmaker Novo Nordisk (NVO) has implemented a hiring freeze, which will apply across all markets and departments, ...

Novo Nordisk, the Denmark-based pharmaceutical company that makes Ozempic and Wegovy, looks like it's being toppled off its ...

Novo Nordisk has a commercial relationship with Economist Impact, a division of The Economist Group. The Economist operates ...

Maziar Mike Doustdar takes office as NVO's new CEO, bringing a proven global growth record to tackle rising obesity market ...

Several months after unveiling its direct-to-consumer NovoCare Pharmacy service with the launch of a $499 cash-pay option for ...

Maziar Mike Doustdar, who was named as Novo Nordisk’s new CEO last week, spoke on a second quarter earnings call of reallocating resources to the company’s “main core” of metabolic disease.

Novo Nordisk is slashing the cost of Ozempic for cash-paying patients after the diabetes shot became the poster child for ...

U.S.-listed shares of Novo Nordisk sank in premarket trading Tuesday after the Danish drugmaker cut its full-year outlook and ...

Novo Nordisk is attractively valued after the sell-off, but near-term recovery requires patience. Read why I'm downgrading NVO stock from Strong Buy to Buy.

Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...

The health and beauty firm behind the Myprotein brand has said its profits will fall by £13m because of the high price of key ...